Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that moderate to severe androgenetic alopecia is an independent predictor of increased mortality risk from diabetes mellitus and heart disease in both sexes.

This expert panel review developed consensus recommendations for managing androgenetic alopecia in Canadian adults, endorsing seven interventions like oral and topical medications and platelet-rich plasma.

This study found that ACOD1 deficiency in dermal papilla cells promotes mitochondrial dysfunction and contributes to cellular senescence in androgenetic alopecia, suggesting ACOD1 as a potential therapeutic target and 4-octyl itaconate as a promising treatment option for AGA.

This study found that the leaf extract of Tectona grandis and its major bioactive constituents moderately inhibit the 5α-reductase enzyme, which is linked to androgenetic alopecia, and also possess anti-inflammatory properties, showing promise as dual-action candidates for managing this condition.

In this case study, a 10-month-old minority infant from Xinjiang, China, with acrodermatitis enteropathy caused by an SLC39A4 gene mutation showed clinical improvement and increased zinc levels following zinc supplementation, highlighting the importance of early genetic testing and customized treatment in managing the disorder.

This report describes a 28-year-old male with type 1 diabetes who presented with acrodermatitis enteropathica symptoms, highlighting potential challenges in blood glucose control linked to zinc deficiency.

This review discusses the lack of long-term clinical studies on metformin's cardiovascular benefits in women with polycystic ovary syndrome, highlighting lifestyle changes as a crucial management strategy for reducing associated risks.

Treatments for hair loss include hormone modifiers, minoxidil, and hair transplant surgery.

This study reports that ritlecitinib 50 mg, with or without an initial loading dose, demonstrated meaningful and sustained efficacy up to 24 months in the Asian subpopulation with severe alopecia areata, showing significant scalp, eyebrow, and eyelash hair regrowth, along with an acceptable safety profile.

In this study, chemotherapy regimens for lung cancer in Indonesian patients were found to be guideline-congruent, but adverse effects like anemia and hair loss were common, suggesting a need for managing these to optimize treatment.

This review discusses caffeine's potential role in treating androgenetic alopecia by counteracting DHT effects on hair follicles and enhancing cell proliferation, but reports no new clinical results.

This case report describes a 52-year-old woman with erythema annulare centrifugum after using topical luliconazole and oral itraconazole, suggesting a drug-induced reaction confirmed by a positive rechallenge test.

In this study, seven patients with refractory alopecia areata treated with concentrated growth factor and microneedling-assisted betamethasone experienced significant hair regrowth, with one achieving over 50% regrowth and six showing complete recovery, without adverse effects.

This study developed a consensus document to guide danazol discontinuation in hereditary angioedema patients, enhancing the standardization and safety of treatment protocols.

This review explores the inconsistent therapeutic effects and side effects of finasteride for androgenic alopecia, highlighting the need for further research to better predict individual patient responses.

The lotion helps manage mild to moderate hair loss.

In this study, Ritlecitinib was reported as a newly approved treatment for alopecia areata that can be used in patients aged 12 and older; after 24 weeks, it resulted in 80% or more scalp hair coverage in treated patients compared to a placebo.

This study found that men with early-onset androgenetic alopecia had larger prostate volumes and lower urinary flow rates compared to those without the condition, suggesting a potential link between AGA and urinary symptoms.

This study found that young males with stage III or higher androgenetic alopecia had higher insulin resistance and cardiovascular-related features, suggesting the need for metabolic assessment in this population.

This case report describes a 7-month-old girl diagnosed with acrodermatitis enteropathica, linked to low zinc levels, whose skin lesions improved significantly after zinc supplementation.

This case report describes a 21-year-old woman with circumscribed alopecia areata incognita, who experienced a sustained positive response to treatment with oral tofacitinib after conventional treatments frequently failed to provide lasting effects.

This study found that CPA-loaded nanoparticles, particularly SLN formulations, increased CPA epidermal penetration compared to a conventional cream and may reduce side effects in treating androgen-dependent conditions.

This study found that non-ablative Er:YAG laser treatment, alone or combined with other therapies, effectively improved hair quality and reduced AGA grade in patients, with high satisfaction reported and no adverse reactions.

This study noted that among hospitalized COVID-19 patients, androgenetic alopecia was prevalent, and severe cases were associated with adverse outcomes such as respiratory failure, highlighting a possible link with androgen sensitivity.

This study found that androgenetic alopecia is significantly associated with an increased risk of Metabolic Syndrome, particularly in early-onset male cases and females exhibiting severe AGA.

This study reported 14 cases of frontal edema following mesotherapy for androgenetic alopecia, suggesting clinicians should be aware of this potential side effect.

In this study, JAK inhibitors for treating alopecia areata and atopic dermatitis were generally well tolerated in a real-world setting, with most adverse events being mild or moderate and rare serious cases resembling the general population incidence.

This study predicted that key components of Platycladi Cacumen, such as quercetin and apigenin, may have stable binding interactions with targets involved in androgenetic alopecia.

In this real-world study, aumolertinib was found to improve patient-reported outcomes and maintain high disease control and objective response rates similar to those reported in the AENEAS trial for advanced NSCLC patients, supporting its use in first-line treatment.